The aim of this paper is to analyze on clinical cases specific features of femoral insufficiency fractures during bisphosphonates therapy. We are presenting two insufficiency femoral fractures (2 patients) in patients receiving bisphosphonate therapy. These two cases represent new type of femoral fractures. These are low energy or spontaneous fractures of diaphysis and subtrochanteric region. Prodromal pain is often observed. On x-rays thick lateral cortex, its ellipsoid thickening and transverse or oblique fracture line is observed. Many authors link such fractures to long-term bisphosphonate therapy. Patients on long term bisphosphonate therapy present with new and specific fracture pattern of femoral bone. Fractures of this pattern are extremely rare. The risk benefit ratio of bisphosphonates therapy is not changed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5604/15093492.950418 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the effects of bisphosphonate therapy on the temporomandibular joint using cone beam computed tomography.
Oral Radiol
March 2025
Faculty of Dentistry, Departmant of Oral and Maxillofacial Radiology, Akdeniz University, Konyaaltı, 07058, Antalya, Turkey.
Objective: The aim of this study was to evaluate the mandibular condyle and articular eminences of patients diagnosed with medication-related osteonecrosis of the jawbone (MRONJ) and those who use bisphosphonates (BP) but do not have MRONJ findings, by comparing them with a healthy control group.
Methods: The cone beam computed tomography (CBCT) images of 20 patients (15 male, 5 female) who were diagnosed with MRONJ and 20 patients (16 male and 4 female) who were using bisphosphonates but had no MRONJ were included in the study. A control group consisted of 20 age- and gender-matched patients (13 male, 7 female) who had no clinical complaints or signs and symptoms of TMD or rheumatic disease.
Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross-sectional study.
Br J Clin Pharmacol
March 2025
Department of Pharmacology & Therapeutics, Trinity College Dublin, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland.
Aim: Osteoporosis is a prevalent skeletal disease characterized by low bone mass and increased fracture risk. Management of osteoporosis typically involves antiresorptive and anabolic therapies, which are reimbursed in Ireland through various drug schemes. This study aims to summarize the utilization patterns associated with medicines used in the management of osteoporosis in Ireland.
View Article and Find Full Text PDFDenosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures.
J Bone Miner Res
March 2025
Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia.
Denosumab is a highly effective treatment for osteoporosis, and its long-term use is associated with incremental gains in bone mineral density (BMD) and sustained fracture risk reduction. Stopping denosumab, however, results in rebound increase in bone turnover, loss of treatment-associated BMD gains, and in the worst case, spontaneous vertebral fractures (VFs). Insights into the risk factors and the underlying mechanisms for rebound-associated bone loss and true incidence of rebound VFs are emerging.
View Article and Find Full Text PDFDenosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach.
Aging Clin Exp Res
March 2025
Interdisciplinary Center of Bone Diseases, Rheumatology Unit, Bone and Joint Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Denosumab produces a continuous increase in bone mineral density over ten years, associated with a low risk of vertebral and non-vertebral fractures. Denosumab is well tolerated and easy to manage in daily clinical practice. For all these reasons, this treatment has a huge success.
View Article and Find Full Text PDFImpact of the FLS model on patients with major fracture in Gran Canaria: 2018-2022 experience.
Arch Osteoporos
March 2025
Rheumatology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena, 35011, Las Palmas de Gran Canaria, Spain.
Unlabelled: We analyzed 5396 patients with fragility fracture, their inclusion by the FLS, and prescription of treatment. Thirty-four percent of potential cases were attended by the FLS, and at the healthcare level, the impact of FLS model resulted in an increase of treated patients from 20% in standard care to 41%.
Introduction: Patients with fragility fractures are at high risk of new fractures, with a negative impact on their quality of life, as well as higher mortality and costs for the health system, especially for hip fractures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!